<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266457</url>
  </required_header>
  <id_info>
    <org_study_id>AC20015</org_study_id>
    <nct_id>NCT04266457</nct_id>
  </id_info>
  <brief_title>Establishing Alpha-synuclein RT-QuIC Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder</brief_title>
  <official_title>Establishing Alpha-synuclein Real Time - Quaking Induced Conversion (RT-QuIC) Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder (RBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weston Brain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesise that a real-time quaking induced conversion assay for the detection of
      pathological alpha-synuclein (α -syn RTQuIC) can be used to differentiate between cases of
      idiopathic REM-sleep behaviour disorder (RBD) and RBD that is symptomatic of prodromal
      α-synucleinopathies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be the largest analysis of CSF α-synuclein in RBD patients to date. In line
      with the The National CJD Research &amp; Surveillance Unit (NCJDRSU)'s recent inclusion of a
      positive RT-QuIC for pathological prion protein in the diagnostic criteria for
      Creutzfeldt-Jakob Disease (CJD) [1], we aim to deploy this novel method to establish it as an
      accurate research and diagnostic resource in the assessment and prognosis of RBD. This
      research is transformative and has the potential to change practice.

      Currently, there is no simple method with high sensitivity and specificity available which
      can identify patients who will go on to develop an α - synucleinopathy. Clinical assessment
      of a panel of markers (e.g. Postuma et al. 2015) are time-consuming and impractical in normal
      clinical settings, with the majority of patients presenting to sleep physicians,
      geriatricians, and non-specialised neurology clinics, both publicly and privately. This has a
      major impact on counselling strategies for RBD patients, appropriate follow-up, trials of
      novel neuro-protective agents in alpha-synucleinopathies before full-blown phenotype is
      manifest and enhancing understanding of pathways involved in RBD out-with the dopaminergic
      system.

      RBD is a common, sometimes fatal disease (through injury to self/others) and treatments are
      indiscriminate regarding aetiology with limited evidence-base. A simple test using CSF
      (analogous to measuring CSF-orexin levels to diagnose narcolepsy+cataplexy) with high
      sensitivity and specificity is ideal. Thus, we believe that the central thesis of our work
      will not only inform subsequent behavioural, genetic and neuroimaging characterisation of our
      established RBD cohort, but will also translate the α-syn RT-QuIC concept into evidence-based
      and effective clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prescence of pathological α-synuclein within the CSF</measure>
    <time_frame>0-24 months after sample taken</time_frame>
    <description>The primary outcome measure will be either a positive/negative (binary) result from the α-syn RT-QuIC assay. A positive output confirms presence of pathological α-synuclein within the CSF.</description>
  </primary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Sleep Disorder Rem Sleep Behavior</condition>
  <condition>Parkinson's Disease, Lewy Body</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No Intervention</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5ml ceberospinal fluid, 9ml blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with REM Sleep Behavioural Disorder using ICSD-3 criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with RBD using ICSD-3 criteria [18] - Patients aged 18 years and
             over - Patient able to give written informed consent

        Exclusion Criteria:

          -  RBD secondary to medication or withdrawal state. - &lt;18 years old - Inability to give
             written informed consent - Contraindication to lumbar puncture procedure (e.g.
             patients taking Warfarin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renata L Riha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenny Scott</last_name>
    <phone>+441312423025</phone>
    <email>accord@nhslothian.scot.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jo-Anne Robertson</last_name>
    <phone>+441312423326</phone>
    <email>resgov@accord.scot</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015 Mar 17;84(11):1104-13. doi: 10.1212/WNL.0000000000001364. Epub 2015 Feb 13.</citation>
    <PMID>25681454</PMID>
  </reference>
  <reference>
    <citation>Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, Sanchez-Valle R, Vilaseca I, Lomeña F, Vilas D, Lladó A, Gaig C, Santamaria J. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013 May;12(5):443-53. doi: 10.1016/S1474-4422(13)70056-5. Epub 2013 Apr 3.</citation>
    <PMID>23562390</PMID>
  </reference>
  <reference>
    <citation>Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh M, Adler C, Woodruff B, Beach TG, Iranzo A, Gelpi E, Santamaria J, Tolosa E, Singer C, Mash DC, Luca C, Arnulf I, Duyckaerts C, Schenck CH, Mahowald MW, Dauvilliers Y, Graff-Radford NR, Wszolek ZK, Parisi JE, Dugger B, Murray ME, Dickson DW. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013 Aug;14(8):754-62. doi: 10.1016/j.sleep.2012.10.015. Epub 2013 Mar 7.</citation>
    <PMID>23474058</PMID>
  </reference>
  <reference>
    <citation>Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013 Aug;14(8):744-8. doi: 10.1016/j.sleep.2012.10.009. Epub 2013 Jan 22.</citation>
    <PMID>23347909</PMID>
  </reference>
  <reference>
    <citation>Plomhause L, Dujardin K, Duhamel A, Delliaux M, Derambure P, Defebvre L, Monaca Charley C. Rapid eye movement sleep behavior disorder in treatment-naïve Parkinson disease patients. Sleep Med. 2013 Oct;14(10):1035-7. doi: 10.1016/j.sleep.2013.04.018. Epub 2013 Jul 25.</citation>
    <PMID>23890957</PMID>
  </reference>
  <reference>
    <citation>Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211.</citation>
    <PMID>12498954</PMID>
  </reference>
  <reference>
    <citation>Kim YK, Yoon IY, Kim JM, Jeong SH, Kim KW, Shin YK, Kim BS, Kim SE. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur J Neurol. 2010 Mar;17(3):487-92. doi: 10.1111/j.1468-1331.2009.02854.x. Epub 2009 Nov 24.</citation>
    <PMID>19968708</PMID>
  </reference>
  <reference>
    <citation>Barber TR, Lawton M, Rolinski M, Evetts S, Baig F, Ruffmann C, Gornall A, Klein JC, Lo C, Dennis G, Bandmann O, Quinnell T, Zaiwalla Z, Ben-Shlomo Y, Hu MTM. Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. Sleep. 2017 Aug 1;40(8). doi: 10.1093/sleep/zsx071.</citation>
    <PMID>28472425</PMID>
  </reference>
  <reference>
    <citation>Puschmann A, Bhidayasiri R, Weiner WJ. Synucleinopathies from bench to bedside. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S24-7. doi: 10.1016/S1353-8020(11)70010-4. Review.</citation>
    <PMID>22166445</PMID>
  </reference>
  <reference>
    <citation>Peelaerts W, Baekelandt V. ɑ-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem. 2016 Oct;139 Suppl 1:256-274. doi: 10.1111/jnc.13595. Epub 2016 Mar 30. Review.</citation>
    <PMID>26924014</PMID>
  </reference>
  <reference>
    <citation>Tyson T, Steiner JA, Brundin P. Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem. 2016 Oct;139 Suppl 1:275-289. doi: 10.1111/jnc.13449. Epub 2016 Feb 10. Review.</citation>
    <PMID>26617280</PMID>
  </reference>
  <reference>
    <citation>El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006 Mar;20(3):419-25.</citation>
    <PMID>16507759</PMID>
  </reference>
  <reference>
    <citation>Tinsley RB, Kotschet K, Modesto D, Ng H, Wang Y, Nagley P, Shaw G, Horne MK. Sensitive and specific detection of α-synuclein in human plasma. J Neurosci Res. 2010 Sep;88(12):2693-700. doi: 10.1002/jnr.22417.</citation>
    <PMID>20648655</PMID>
  </reference>
  <reference>
    <citation>Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, Hasegawa M, Taylor M, Mann D, Allsop D. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 2011 Dec;25(12):4127-37. doi: 10.1096/fj.10-179192. Epub 2011 Aug 24.</citation>
    <PMID>21865317</PMID>
  </reference>
  <reference>
    <citation>Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. Acta Neuropathol. 2017 Apr;133(4):535-545. doi: 10.1007/s00401-017-1684-z. Epub 2017 Feb 8.</citation>
    <PMID>28180961</PMID>
  </reference>
  <reference>
    <citation>Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MT, Parkkinen L, Green AJ. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016 Aug 28;3(10):812-818. eCollection 2016 Oct.</citation>
    <PMID>27752516</PMID>
  </reference>
  <reference>
    <citation>Li SX, Wing YK, Lam SP, Zhang J, Yu MW, Ho CK, Tsoh J, Mok V. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep Med. 2010 Jan;11(1):43-8. doi: 10.1016/j.sleep.2009.06.008. Epub 2009 Nov 30.</citation>
    <PMID>19945912</PMID>
  </reference>
  <reference>
    <citation>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5.</citation>
    <PMID>1798888</PMID>
  </reference>
  <reference>
    <citation>Holmes TH, Rahe RH. The Social Readjustment Rating Scale. J Psychosom Res. 1967 Aug;11(2):213-8.</citation>
    <PMID>6059863</PMID>
  </reference>
  <reference>
    <citation>Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.</citation>
    <PMID>19025984</PMID>
  </reference>
  <reference>
    <citation>White C, Hill EA, Morrison I, Riha RL. Diagnostic delay in REM sleep behavior disorder (RBD). J Clin Sleep Med. 2012 Apr 15;8(2):133-6. doi: 10.5664/jcsm.1762.</citation>
    <PMID>22505857</PMID>
  </reference>
  <reference>
    <citation>Alberio T, Bossi AM, Milli A, Parma E, Gariboldi MB, Tosi G, Lopiano L, Fasano M. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis. FEBS J. 2010 Dec;277(23):4909-19. doi: 10.1111/j.1742-4658.2010.07896.x. Epub 2010 Oct 26.</citation>
    <PMID>20977677</PMID>
  </reference>
  <reference>
    <citation>Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010 Dec;33(12):559-68. doi: 10.1016/j.tins.2010.09.004. Epub 2010 Oct 18. Review.</citation>
    <PMID>20961626</PMID>
  </reference>
  <reference>
    <citation>Taylor TN, Potgieter D, Anwar S, Senior SL, Janezic S, Threlfell S, Ryan B, Parkkinen L, Deltheil T, Cioroch M, Livieratos A, Oliver PL, Jennings KA, Davies KE, Ansorge O, Bannerman DM, Cragg SJ, Wade-Martins R. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse. Neurobiol Dis. 2014 Feb;62:193-207. doi: 10.1016/j.nbd.2013.10.005. Epub 2013 Oct 10.</citation>
    <PMID>24121116</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>REMBD</keyword>
  <keyword>REM Behavioural Disorder</keyword>
  <keyword>prodromal α-synucleinopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

